GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » Research & Development

NGENF (NervGen Pharma) Research & Development : $10.18 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NervGen Pharma's Research & Development for the three months ended in Sep. 2024 was $3.22 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $10.18 Mil.


NervGen Pharma Research & Development Historical Data

The historical data trend for NervGen Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Research & Development Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 4.92 4.81 5.37 12.23 6.00

NervGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 1.99 2.20 2.77 3.22

NervGen Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (OTCPK:NGENF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


NervGen Pharma Research & Development Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

From GuruFocus